Anti‐PD‐1/PD‐L1 therapy was an approach to ‘‘immune normalization,” which selectively restored the tumor‐induced immune deficiency in the tumor microenvironment (TME) with fewer immune‐related adverse events (irAEs).6 This evidence concerns the gene PDCD1 and neoplasm.